Combination chemotherapy of small-cell bronchogenic carcinoma with etoposide (VP-16), ifosfamide and vindesine (VPIV), and with adriamycin, cis-platinum and vincristine (APO).
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine
D000970:Antineoplastic Agents; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D011034:Podophyllotoxin; D002945:Cisplatin; D014751:Vindesine; D007069:Ifosfamide